About Allozyne
Allozyne is a Healthcare company based in Seattle (United States) founded in 2005 by Dee Datta and William Goddard, and was acquired by MedImmune in September 2014. Protein therapeutics for CNS diseases like multiple sclerosis are developed. Allozyne has raised $40.46 million across 6 funding rounds from investors including ARE, Arch Venture Partners and MedImmune. The company has 6 employees. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Cytokines and Neurology. Its legal entity is ALLOZYNE, INC. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Allozyne was founded in 2005 in Seattle, United States, within the biotechnology sector. Technologies are developed and commercialized to enhance efficacy, safety, and dosing of protein-based therapeutics, including peptides, antibodies, and vaccines. A PEGylated IFN beta product was created for multiple sclerosis treatment. Platforms enable amino acid analogue incorporation for improved biologics and next-generation antibody-drug conjugates. The company was acquired by MedImmune in 2014.
- Headquarters Seattle, United States
- Employees 6
- Founders Dee Datta, William Goddard
- Stage Acquired
- SectorsHealthcare
- Website allozyne.com
- Social LinkedIn
- Acquired by MedImmune (Sep 2014)
- Legal Name Allozyne, Inc.
Funding Insights of Allozyne
Allozyne has successfully raised a total of $40.46M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $2.45 million completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40.46M
- Total Rounds 6
- Last Round Series B — $2.45M
- First Round $3.5M
(Dec 2005)
- Investors Count 6
All 6 funding rounds of Allozyne with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2013 | $2.45M | Series B | – | – | – |
| Apr 2013 | $900,000 | Debt – Conventional | – | – | – |
| Jun 2012 | $2M | Series B | – | – | – |
| Feb 2012 | $2.5M | Series B | – | – | – |
| Oct 2007 | $30M | Series B | – | MPM Capital | |
| Dec 2005 | $3.5M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Allozyne
Allozyne has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Arch Venture Partners and MedImmune.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Early-stage VC investments are focused primarily on US companies. | ovpevents.com | Seattle, United States | ||
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Venture capital services are offered for early-stage biotech companies. | acceleratorlsp.com | Seattle, United States | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Biologic R&D for oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases | 1987 | medimmune.com | Gaithersburg, United States |
Investor details for Allozyne
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allozyne
2 people are tracked at Allozyne (2 in leadership); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Dee Datta | Ex-Co-Founder | Leadership |
William Goddard | Founder | Leadership |
Complete people profiles for Allozyne
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Allozyne
4 dated milestones of Allozyne across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Allozyne is founded.
- Funding First funding round of $3.5M.
- Funding Latest funding round, Series B, of $2.5M.
- Exit Acquired by MedImmune.
Competitors of Allozyne
Allozyne has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Allozyne
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Allozyne
Websites that share an audience with Allozyne (allozyne.com).
Websites whose visitors overlap most with Allozyne. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
istartsurf.com | istartsurf.com | 100% | – | ||
| vlstcorp.com | 100% | 680.7K | View details | ||
| insilicos.com | 100% | View details | |||
spaltudaq.com | spaltudaq.com | 100% | – | ||
acceleratorcorp.com | acceleratorcorp.com | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Allozyne
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Allozyne (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Allozyne
Complete news archive for Allozyne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allozyne
Allozyne was founded in 2005.
Allozyne is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Allozyne is a funded company, having raised a total of $40.46M across 6 funding rounds to date. The company's 1st funding round was a Series A of $3.5M, raised on Dec 2005.
Allozyne has 6 employees.
Allozyne was founded in 2005 in Seattle, United States, within the biotechnology sector. Technologies are developed and commercialized to enhance efficacy, safety, and dosing of protein-based therapeutics, including peptides, antibodies, and vaccines. A PEGylated IFN beta product was created for multiple sclerosis treatment. Platforms enable amino acid analogue incorporation for improved biologics and next-generation antibody-drug conjugates. The company was acquired by MedImmune in 2014.
Allozyne's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Allozyne has 7 investors. Key investors include ARE, Arch Venture Partners, MedImmune, Turmeric Acquisition Corp, and OVP Venture Partners.
Allozyne operates through Allozyne, Inc..
Yes. Allozyne was acquired by MedImmune in September 2014.